Planning instruments enhance the acceptance of urban densification.

Dense and compact cities yield several benefits for both the population and the environment, including the containment of urban sprawl, reduced carbon emissions, and increased housing supply. Densification of the built environment is thus a key contemporary urban planning paradigm worldwide. However, local residents often oppose urban densification, motivating a need to understand their underlying concerns. In order to do so, we examined different factors driving public acceptance of housing densification projects through a combination of a conjoint survey experiment and different proximity frames among 12,402 participants across Berlin, Chicago, London, Los Angeles, New York, and Paris. Respondents compared housing densification projects with varying attributes, including their geographic proximity, project-related factors, and accompanying planning instruments. The results indicate that the acceptance of such projects decreases with project proximity and that project-related factors, such as the type of investor, usage, and climate goals, impact densification project acceptance. More specifically, we see a negative effect on acceptance levels for projects with for-profit investors and a positive effect when the suggested developments are mixed use or climate neutral. In addition, planning instruments, such as rent control, inclusionary zoning, and participatory planning, appear to positively influence acceptance. Interestingly, a cross-continental comparison shows overall higher acceptance levels of densification by US respondents. These multifaceted results allow us to better understand what drives people's acceptance of housing projects and how projects and planning processes can be designed to increase democratic acceptance of urban densification.

Screening for NPHS2 mutations may help predict FSGS recurrence after transplantation.

Steroid-resistant focal segmental glomerulosclerosis (FSGS) often recurs after renal transplantation. In this international survey, we sought to identify genotype-phenotype correlations of recurrent FSGS. We surveyed 83 patients with childhood-onset primary FSGS who received at least one renal allograft and analyzed 53 of these patients for NPHS2 mutations. The mean age at diagnosis was 6.7 years, and the mean age at first renal transplantation was 13 years. FSGS recurred in 30 patients (36%) after a median of 13 days (range, 1.5 to 152 days). Twenty-three patients received a second kidney transplant, and FSGS recurred in 11 (48%) after a median of 16 days (range, 2.7 to 66 days). None of the 11 patients with homozygous or compound heterozygous NPHS2 mutations developed recurrent FSGS compared with 45% of patients without mutations. These data suggest that genetic testing for pathogenic mutations may be important for prognosis and treatment of FSGS both before and after transplantation.

An assessment of the antinociceptive efficacy of intrathecal and epidural contulakin-G in rats and dogs.

Contulakin-G is a novel conopeptide with an incompletely defined mechanism of action. To assess nociceptive activity we delivered Contulakin-G as a bolus intrathecally (0.03, 0.1, 0.3, 3 nmol) or epidurally (10, 30, 89 nmol) in rats. Intrathecal Contulakin G significantly decreased Phase II and, to a lesser degree, Phase I paw flinching produced by intradermal formalin. Intrathecal and epidural doses of ED50s were 0.07 nmol and 45 nmol, respectively, giving an epidural/intrathecal ED50 ratio = 647). In dogs, intrathecal Contulakin-G (50-500 nmoL) produced a dose-dependent increase in the thermally evoked skin twitch latency by 30 min after administration, as did morphine (150 and 450 nmol). Epidural morphine (750 and 7500 nmol), but not epidural 1000 nmol Contulakin-G, also significantly decreased skin twitch in dogs. No changes in motor function were seen in any rats or dogs receiving these doses of Contulakin-G. In dogs, no physiologically significant dose-dependent changes in motor function, heart rate, arterial blood pressure, or body temperature were found. Contulakin-G is a potent antinociceptive drug when delivered intrathecally with no observable negative side effects in rats or dogs and may provide an alternative to opioid spinal analgesics.